BT062 in Combination With Lenalidomide or Pomalidomide and Dexamethasone in Patients With Multiple Myeloma
Status: | Active, not recruiting |
---|---|
Conditions: | Blood Cancer, Hematology |
Therapuetic Areas: | Hematology, Oncology |
Healthy: | No |
Age Range: | 18 - Any |
Updated: | 9/2/2017 |
Start Date: | July 2012 |
End Date: | November 2018 |
A Phase I/IIa Multi-dose Escalation Study of BT062 in Combination With Lenalidomide or Pomalidomide and Dexamethasone in Subjects With Relapsed or Relapsed/Refractory Multiple Myeloma
The purpose of this study is to test safety and anti-tumor activity of BT062 in combination
with lenalidomide and dexamethasone to define the best doses for treating patients with
relapsed and refractory multiple myeloma.
with lenalidomide and dexamethasone to define the best doses for treating patients with
relapsed and refractory multiple myeloma.
BT062 is an antibody-drug conjugate designed to bind and destroy Myeloma cells. The study
drug is being given in multiple doses with standard Multiple Myeloma treatments, lenalidomide
and dexamethasone, to test how well the treatments are tolerated and work together. This
study is a dose escalation study with the purpose to find out the highest dose of BT062 that
a subject can tolerate in combination with lenalidomide and dexamethasone.
drug is being given in multiple doses with standard Multiple Myeloma treatments, lenalidomide
and dexamethasone, to test how well the treatments are tolerated and work together. This
study is a dose escalation study with the purpose to find out the highest dose of BT062 that
a subject can tolerate in combination with lenalidomide and dexamethasone.
Inclusion Criteria
- Diagnosis of active Multiple Myeloma according to the International Myeloma Working
Group (IMWG) diagnostic criteria
- Relapsed or relapsed/refractory progressive Multiple Myeloma
- Subjects who failed at least one prior therapy (BT062/Len/dex)
- Subjects who failed at least two prior therapy (BT062/Pom/dex)
- Subjects age ≥18 years
- Life expectancy of ≥12 weeks
- Eastern Cooperative Oncology Group (ECOG) performance status (Zubrod) ≤2
- Normal organ and bone marrow
- Signed written informed consent in accordance with federal, local, and institutional
guidelines
- Subjects must agree to follow all Guidelines from REVLIMID REMS Program or POMALYST
REMS
- Women of child bearing potential (WCBP), must agree to use 2 contraceptive methods
Exclusion Criteria:
- Chemotherapy or radiotherapy within 3 weeks (6 weeks for nitrosoureas or mitomycin C)
prior to day 1 or those who have not recovered from adverse events (AEs) due to agents
administered more than 3 weeks earlier
- Antineoplastic therapy with biological agents within 2 weeks before day 1 or within 5
drug half-lives (t½) prior to first dose, whichever time period is longer
- Concomitant antineoplastic therapies including chemotherapy, radiotherapy, or
biological agents during the study
- Treatment with another investigational drug during the study or within 3 weeks before
day 1 or within 5 drug half-live (t½) prior to first dose, whichever time period is
longer
- Treatment with BT062 in previous studies
- Major surgery within 4 weeks before day 1 (this does not include placement of vascular
access device or tumor biopsies)
- Malignancy within 3 years before day 1, other than the trial indication multiple
myeloma and excluding treated non-melanoma skin cancer, superficial bladder cancer,
carcinoma in-situ of the cervix and prostate carcinoma ≤ Gleason Grade 6 with stable
prostate specific antigen (PSA) levels
- Subjects with plasma cell leukemia (PCL)
- Subjects with deep vein thrombosis (DVT) and Pulmonary embolism (PE) within 3 months
prior to day 1 treatment
- Severe infections necessitating use of antibiotics / antivirals during the screening
period
- Clinically relevant active infection including active hepatitis B or C or human
immunodeficiency virus (HBV, HCV, or HIV) or any other concurrent disease
- Acute or relevant abnormalities in electrocardiogram (ECG)
- Significant cardiac disease
- Pregnant or breast-feeding
- Positive serum or urine pregnancy test
- Hypersensitivity to the active substance or to any of the excipients for study drug
BT062, or history of severe allergic or anaphylactic reaction to therapeutic proteins
(e.g. reaction to vaccination or to biological therapy)
We found this trial at
10
sites
Click here to add this to my saved trials
University of Chicago One of the world's premier academic and research institutions, the University of...
Click here to add this to my saved trials
Mayo Clinic Mayo Clinic's campus in Arizona provides medical care for thousands of people from...
Click here to add this to my saved trials
Mount Sinai Med Ctr Founded in 1852, The Mount Sinai Hospital is a 1,171-bed, tertiary-care...
Click here to add this to my saved trials
Click here to add this to my saved trials
Dana-Farber Cancer Institute Since it’s founding in 1947, Dana-Farber has been committed to providing adults...
Click here to add this to my saved trials
Hackensack University Medical Center Hackensack University Medical Center, part of the Hackensack University Health Network,...
Click here to add this to my saved trials
1441 Eastlake Ave
Los Angeles, California 90033
Los Angeles, California 90033
(323) 865-3000
U.S.C./Norris Comprehensive Cancer Center The USC Norris Comprehensive Cancer Center, located in Los Angeles, is...
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials